Helen C Looker1, Michael Mauer2, Pierre-Jean Saulnier3,4, Jennifer L Harder5, Viji Nair5, Carine M Boustany-Kari6, Paolo Guarnieri6, Jon Hill6, Cordell A Esplin7, Matthias Kretzler5, Robert G Nelson3, Behzad Najafian8. 1. Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona; helen.looker@nih.gov. 2. Department of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota. 3. Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona. 4. Centre Hospitalier Universitaire of Poitiers, Clinical Investigation Center, Institut National de la Santé et de la Recherche Médicale Poitiers, Poitiers, France. 5. Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 6. Cardiometabolic Diseases Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut. 7. Department of Radiology, St Luke's Medical Center, Phoenix, Arizona; and. 8. Department of Pathology, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: In type 1 diabetes, changes in the GFR and urine albumin-to-creatinine ratio (ACR) are related to changes in kidney structure that reflect disease progression. However, such changes have not been studied in type 2 diabetes. METHODS:Participants were American Indians with type 2 diabetes enrolled in a clinical trial oflosartan versus placebo. We followed a subset who underwent kidney biopsy at the end of the 6-year trial, with annual measurements of GFR (by urinary clearance of iothalamate) and ACR. Participants had a second kidney biopsy after a mean follow-up of 9.3 years. We used quantitative morphometric analyses to evaluate both biopsy specimens. RESULTS: Baseline measures for 48 participants (12 men and 36 women, mean age 45.6 years) who completed the study included diabetes duration (14.6 years), GFR (156 ml/min), and ACR (15 mg/g). During follow-up, glomerular basement membrane (GBM) width, mesangial fractional volume, and ACR increased, and surface density of peripheral GBM and GFR decreased. After adjustment for sex, age, ACR, and each morphometric variable at baseline, an increase in ACR during follow-up was significantly associated with increases in GBM width, mesangial fractional volume, and mean glomerular volume, and a decrease in surface density of peripheral GBM. Decline in GFR was not associated with changes in these morphometric variables after additionally adjusting for baseline GFR. CONCLUSIONS: In American Indians with type 2 diabetes and preserved GFR at baseline, increasing ACR reflects the progression of earlier structural glomerular lesions, whereas early GFR decline may not accurately reflect such lesions.
RCT Entities:
BACKGROUND: In type 1 diabetes, changes in the GFR and urine albumin-to-creatinine ratio (ACR) are related to changes in kidney structure that reflect disease progression. However, such changes have not been studied in type 2 diabetes. METHODS:Participants were American Indians with type 2 diabetes enrolled in a clinical trial of losartan versus placebo. We followed a subset who underwent kidney biopsy at the end of the 6-year trial, with annual measurements of GFR (by urinary clearance of iothalamate) and ACR. Participants had a second kidney biopsy after a mean follow-up of 9.3 years. We used quantitative morphometric analyses to evaluate both biopsy specimens. RESULTS: Baseline measures for 48 participants (12 men and 36 women, mean age 45.6 years) who completed the study included diabetes duration (14.6 years), GFR (156 ml/min), and ACR (15 mg/g). During follow-up, glomerular basement membrane (GBM) width, mesangial fractional volume, and ACR increased, and surface density of peripheral GBM and GFR decreased. After adjustment for sex, age, ACR, and each morphometric variable at baseline, an increase in ACR during follow-up was significantly associated with increases in GBM width, mesangial fractional volume, and mean glomerular volume, and a decrease in surface density of peripheral GBM. Decline in GFR was not associated with changes in these morphometric variables after additionally adjusting for baseline GFR. CONCLUSIONS: In American Indians with type 2 diabetes and preserved GFR at baseline, increasing ACR reflects the progression of earlier structural glomerular lesions, whereas early GFR decline may not accurately reflect such lesions.
Authors: Kathryn E White; Rudolf W Bilous; Sally M Marshall; Meguid El Nahas; Giuseppe Remuzzi; Giampiero Piras; Salvatore De Cosmo; GianCarlo Viberti Journal: Diabetes Date: 2002-10 Impact factor: 9.461
Authors: Gudeta D Fufaa; E Jennifer Weil; Kevin V Lemley; William C Knowler; Frank C Brosius; Berne Yee; Michael Mauer; Robert G Nelson Journal: Clin J Am Soc Nephrol Date: 2016-01-20 Impact factor: 8.237
Authors: Helen C Looker; Laura Pyle; Tim Vigers; Cameron Severn; Pierre J Saulnier; Behzad Najafian; Michael Mauer; Robert G Nelson; Petter Bjornstad Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Jae Young Kim; Young Su Joo; Jong Hyun Jhee; Seung Hyeok Han; Tae-Hyun Yoo; Shin-Wook Kang; Jung Tak Park Journal: J Gen Intern Med Date: 2021-01-19 Impact factor: 6.473
Authors: Jennifer A Schaub; Christopher L O'Connor; Jian Shi; Roger C Wiggins; Kerby Shedden; Jeffrey B Hodgin; Markus Bitzer Journal: J Clin Pathol Date: 2021-01-11 Impact factor: 4.463
Authors: Nora Franceschini; Melanie Waldenberger; Pamela R Matías-García; Cavin K Ward-Caviness; Laura M Raffield; Xu Gao; Yan Zhang; Rory Wilson; Xīn Gào; Jana Nano; Andrew Bostom; Elena Colicino; Adolfo Correa; Brent Coull; Charles Eaton; Lifang Hou; Allan C Just; Sonja Kunze; Leslie Lange; Ethan Lange; Xihong Lin; Simin Liu; Jamaji C Nwanaji-Enwerem; Alex Reiner; Jincheng Shen; Ben Schöttker; Pantel Vokonas; Yinan Zheng; Bessie Young; Joel Schwartz; Steve Horvath; Ake Lu; Eric A Whitsel; Wolfgang Koenig; Jerzy Adamski; Juliane Winkelmann; Hermann Brenner; Andrea A Baccarelli; Christian Gieger; Annette Peters Journal: Clin Epigenetics Date: 2021-06-02 Impact factor: 7.259
Authors: Pierre J Saulnier; Helen C Looker; Michael Mauer; Behzad Najafian; Elise Gand; Stephanie Ragot; Robert G Nelson; Petter Bjornstad Journal: Diabetes Date: 2021-07-13 Impact factor: 9.337
Authors: Robert G Nelson; William C Knowler; Matthias Kretzler; Kevin V Lemley; Helen C Looker; Michael Mauer; William E Mitch; Behzad Najafian; Peter H Bennett Journal: Diabetes Date: 2021-07-20 Impact factor: 9.337